{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=19", "query": { "intervention": "Level B", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 1431, "total_pages": 144, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T11:06:57.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07168486", "title": "CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Diffuse Large B Cell Lymphoma (DLBCL)", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Follicular Lymphoma", "Transformed Follicular Lymphoma (tFL)", "Mantle Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Richter Transformation", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "CD19.20.22 CAR T cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine and Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-10-28", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07168486" }, { "nct_id": "NCT04669587", "title": "ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Estrogen Receptor-Positive", "HER2-Negative", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "ZB716", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EnhancedBio USA Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-07-26", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04669587" }, { "nct_id": "NCT02091999", "title": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Cancer and Other Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2014-05-14", "completion_date": "2022-12-07", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 18, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091999" }, { "nct_id": "NCT03850678", "title": "Restoration of Spectral Resolution With Hearing-aid Amplification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hearing Loss" ], "interventions": [ { "name": "Hearing Aid", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Nebraska Lincoln", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 209, "start_date": "2019-04-02", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03850678" }, { "nct_id": "NCT05025800", "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Composite Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Follicular Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma", "Richter Syndrome" ], "interventions": [ { "name": "CD47 Antagonist ALX148", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-10-13", "completion_date": "2028-03-21", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025800" }, { "nct_id": "NCT03686124", "title": "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer" ], "interventions": [ { "name": "IMA203 Product", "type": "BIOLOGICAL" }, { "name": "IMA203 product- flat dose", "type": "BIOLOGICAL" }, { "name": "IMA203CD8 Product", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2019-05-14", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 13, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686124" }, { "nct_id": "NCT06256484", "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ATA3219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atara Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2024-09-06", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 4, "location_summary": "Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06256484" }, { "nct_id": "NCT05977036", "title": "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Breast Cancer", "Unresectable Breast Cancer" ], "interventions": [ { "name": "DiviTum® TKa assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2024-09-25", "completion_date": "2035-09-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977036" }, { "nct_id": "NCT00974064", "title": "The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)", "Smoking", "Smoking Cessation", "Chronic Bronchitis", "Emphysema" ], "interventions": [], "intervention_types": [], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2009-08", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00974064" }, { "nct_id": "NCT03917407", "title": "DUR-928 in Patients With Alcoholic Hepatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcoholic Hepatitis" ], "interventions": [ { "name": "DUR-928 (Moderate AH)", "type": "DRUG" }, { "name": "DUR-928 (Severe AH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig James McClain", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "21 Years to 67 Years" }, "enrollment_count": 43, "start_date": "2021-06-01", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-10-23T11:06:57.940Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03917407" } ] }